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Abstract 
Background: Dysregulation of long noncoding RNA (lncRNA) expression contributes to the pathogenesis of many 
human diseases, including liver diseases. Several lncRNAs have been reported to play a role in the development of 
hepatocellular carcinoma (HCC). However, most studies have analyzed lncRNAs only in hepatitis B virus (HBV)-related 
HCC or in a single group of HCC patients regardless of the viral etiology.
Methods: To investigate whether lncRNAs are differentially expressed in HCC of different viral etiology, we profiled 
101 disease-related lncRNAs, including 25 lncRNAs previously associated with HCC, in liver specimens obtained from 
well-characterized patients with HBV-, hepatitis C virus (HCV)-, or hepatitis D virus (HDV)-associated HCC.
Results: We identified eight novel HCC-related lncRNAs that were significantly dysregulated in HCC tissues compared 
to their surrounding non-tumorous tissues. Some of these lncRNAs were significantly dysregulated predominantly in 
one specific hepatitis virus-related HCC, including PCAT-29 in HBV-related HCC, aHIF and PAR5 in HCV-related HCC, 
and Y3 in HDV-related HCC. Among the lncRNAs previously reported in HCC, we found that DBH-AS1, hDREH and 
hPVT1 were differentially expressed in HCC of different viral etiology.
Conclusions: Our study suggests that HCC of different viral etiology is regulated by different lncRNAs. The identifica-
tion of lncRNAs unique to specific hepatitis virus-related HCC may provide new tools for improving the diagnosis of 
HCC and open new avenues for disease-specific therapeutic interventions.
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Background
Recent findings from genome tiling arrays and RNA 
sequencing have revealed the existence of a large num-
ber of RNAs that lack protein-coding capacity, which can 
be divided into two groups, namely, small non-coding 
RNAs (sncRNA) (<200  bp) and long non-coding RNAs 
(lncRNAs) (>200  bp) [1, 2]. Although lncRNAs have 
long been viewed as transcriptional “noise”, increasing 
evidence shows that they function in many cellular pro-
cesses and may play a role in the pathogenesis of cancer 
and other diseases [3, 4]. LncRNAs are involved in both 
transcriptional and post-transcriptional regulation, and 
can contribute structural/scaffolding functions [1].
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide and the second cause of cancer-
related death [5]. Chronic infections with hepatitis B 
virus (HBV), hepatitis C virus (HCV) and hepatitis D 
virus (HDV) account for over 80% of HCC cases [6]. It 
has been estimated that about a half billion people are 
chronically infected with hepatitis viruses worldwide 
(250 million with HBV, 170 million with HCV, and 15 
million with HDV) [7–9]. Studies on the natural history 
of chronic viral hepatitis have shown that over a period of 
10–40 years about 30% of patients will develop cirrhosis 
and its long-term consequences, liver decompensation 
and/or HCC [10], leading to liver-related death or liver 
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hepatitis viruses and HCC has been well established, the 
molecular mechanisms whereby hepatitis viruses induce 
liver cancer remain to be elucidated.
Previous studies on the molecular pathogenesis of 
HCC were mainly focused on investigating the role of 
protein-coding genes. However, there is increasing inter-
est in the study of non-coding RNAs, including sncRNAs 
and lncRNAs [11]. Although extensive studies have been 
performed on sncRNAs, in particular microRNAs (miR-
NAs), our understanding of the lncRNA functions in 
HCC is still limited. Several lncRNAs have been shown to 
be involved in the development of HCC, providing new 
insights into pathogenesis and highlighting lncRNAs as 
potential diagnostic, prognostic and therapeutic factors 
in this cancer [12]. However, a major limitation of pre-
vious studies is that they either analyzed lncRNAs selec-
tively in HBV-related HCC or considered HCC as a single 
group regardless of the hepatitis virus involved. In this 
study, we analyzed the expression of lncRNAs in HBV-, 
HCV-, and HDV-related HCC patient samples, with the 
aim of investigating the differential role of lncRNAs in 
relation to the different viral etiology of HCC.
Methods
Patients
We studied a total of 63 patients. Twenty-five patients 
had viral-associated HCC. The etiology was infection 
with HBV in 11 patients, HCV in 10 and HDV in 4. 
Twenty had non-HCC cirrhosis; the etiology was infec-
tion with HBV in 3, HCV in 10 and HDV in 7. The con-
trol group included 10 liver donors and 8 subjects who 
underwent liver resection for hepatic hemangioma. All 
patients were negative for human immunodeficiency 
virus type-1. For each liver biopsy specimen, the stage of 
fibrosis and the activity grade were evaluated according 
to the Ishak scoring system [13]. The grade of tumor dif-
ferentiation was established according to the Edmondson 
and Steiner grading system [14]. Patients were followed at 
the Liver Transplantation Center of the Brotzu Hospital 
in Cagliari, Italy. All patients provided written informed 
consent, and the protocol was approved by the ethical 
Committee of the Hospital Brotzu, Cagliari, Italy. The 
study was also approved by the Office of Human Subjects 
Research of the National Institutes of Health, Bethesda, 
MD, on the condition that all samples were de-identified.
Liver specimens for the expression of long‑noncoding 
RNAs
Among the 25 individuals with viral-associated HCC who 
underwent liver transplantation, two liver specimens 
were obtained from each patient, including one from the 
tumor and one from the surrounding non-tumorous tis-
sue, while individual specimens were obtained from 20 
patients with non-HCC cirrhosis of different viral etiol-
ogy who had never developed HCC and underwent liver 
transplantation for end-stage liver disease, and from 18 
patients of the control group. Thus, a total of 88 liver 
specimens were analyzed for the expression of lncRNAs 
(Figs.  1a, 2a). Each individual liver biopsy was divided 
into two pieces: one was snap-frozen and stored at −80°C 
for molecular studies and the other was formalin-fixed 
and paraffin-embedded for pathological examination. A 
critical point of our study is that confounding factors, 
such as the presence of a mixed population of tumor and 
non-tumor hepatocytes were completely ruled out, as all 
liver specimens were evaluated by an expert liver hepato-
pathologist and liver specimens containing a mixed cel-
lular population were excluded from this study.
RNA extraction
Total RNA was extracted from frozen liver specimens 
using the miRNeasy Mini Kit (Qiagen, Hilden, Germany). 
The concentration of total RNA was measured using a 
Nano Drop method (Nano Drop Technologies, Wilming-
ton, DE). The quality and integrity of RNA were assessed 
with the RNA 6000 Nano Assay on the Agilent 2100 Bio-
analyzer (Agilent Technologies, Santa Clara, CA).
LncRNAs profiling
Extracted RNA was converted to cDNA using the Proto-
Script® First Strand cDNA Synthesis Kit (New England 
Biolabs, Ipswich, MA). Disease-Related Human LncRNA 
Profiler (System Biosciences, Palo Alto, CA), which is an 
array based on quantitative real-time PCR (qRT-PCR), 
was used to profile lncRNAs in the samples accord-
ing to the manufacturer’s instructions. Eighty-three 
lncRNAs profiled were as follows: 21A, AAA1, aHIF, 
AK023948, ANRIL, anti-NOS2A, BACE1AS, BC017743, 
BC043430, BC200, BCMS, BIC, CCND1ANCR, DD3, 
DGCR5, DISC2, DLG2AS, EGO, GAS5, GOMAFU, 
H19, H19-AS, HAR1A, HAR1B, HOTAIR, HOTAIRM1, 
HOTTIP, HOXA1ASAA489505, HOXA3ASBI823151, 
HOXA3ASBE873349, HOXA6ASAK092154, HOX-
A11AS, HULC, IPW, IGF2AS, KRASP1, L1PA16, LIT, 
LOC285194, LUST, LINC01152, LincRNAVLDLR, Lin-
cRNASFMBT2, MALAT1, MEG3, MER11C, NEAT1, 
NCRMS, NDM29, PANDA, PAR5, PCAT-1, PCAT-
14, PCAT-29, PCAT-32, PCAT-43, PCGEM1, PR-AT2, 
PRINS, PSF inhibiting RNA, PTENP1, RMRP, ROR, 
SAF, SCA8, Sox2OT, SRA, ST7OT1, ST7OT2, ST7OT3, 
ST7OT4, Telomerase RNA, TMEVPG1, TU_0017629, 
TUG1, UCA1, WT1-AS, Y1, Y3, Y4, Y5, ZEB2NAT, 7SK. 
Eleven genes (7SL scRNA, 5.8S rRNA, U87 scaRNA, U6 
smRNA, ACTB, B2 M, PGK1, GAPDH, HPRT1, RPL1A, 
RPL13A) were used as endogenous controls. We also 
analyzed an additional 18 HCC-related lncRNAs by 
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qRT-PCR using the same primers as previously reported 
[15–32] and listed in Additional file 1: Table S1, includ-
ing: AFAP1-AS1, CCAT1, DANCR, DBH-AS1, hDREH, 
GAS5, HEIH, LET, Linc00152, LincTCF7, MVIH, PCNA-
AS1, hPVT1, uc.338, UCA1, UFC1, ZEB-AS1 and 
ZFAS1.
Quantitative real‑time PCR
Quantitative real-time PCR (qRT-PCR) was performed 
using the iQ SYBR Green Supermix (Bio-Rad, Hercu-
les, CA) according to the manufacturer’s instructions. 
GAPDH was used as an endogenous control. LncR-
NAs expression levels were normalized by calculat-
ing the lncRNAs/GAPDH expression ratio (2−ΔCt). The 
relative expression of lncRNAs was calculated as the ratio 
between lncRNAs expression levels (2−ΔCt) in each liver 
specimen and the geometric mean of all normal livers. 
The primer sequences were listed in Additional file  1: 
Table S1. Amplification of qRT-PCR was carried out as 
follows: 95 °C for 3 min, followed by 40 cycles at 95 °C for 
15 s and 60 °C for 60 s.
Principal component analysis and hierarchical clustering
The expression levels of lncRNAs by the profiling or qRT-
PCR were converted to log2 scale and imported into Partek 
Genomics Suite (Partek Inc., St. Louis, MO). The relation-
ships between the exclusive 68 lncRNAs and HCC were 
































Fig. 1 Study design and principal component analysis showing the relationship among the tissue groups in patients with HCC of different viral 
etiology. The analysis was based on the results of the normalized expression levels of 68 long non-coding RNAs (lncRNA) detected in tumor tis-
sues and their surrounding non-tumorous tissues using disease-related human LncRNA Profiler. a Study design illustrating the different groups of 
patients included in the profiling of the expression of disease-related lncRNAs. HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis 
C virus; HDV, hepatitis D virus. b Principal component analysis of tumor (T) and surrounding non-tumor tissue (NT). c Principal component analysis 
of tumor (T) and surrounding non-tumor tissue (NT) of 6 groups of patients according to the viral etiology. Each principal component contribution 
rate is shown in each axis. PCA Principal component analysis; PC principal component
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and hierarchical clustering on the 10 dysregulated genes, in 
which dissimilarity was measured by the Euclidean distance 
and the average linkage method was used for clustering.
Statistical analysis
The differences between groups for the matched samples 
were estimated by Student’s paired t test (two-tailed). 
The one-way analysis of variance (ANOVA) was used 
to determine the differences among the three groups. P 
value <0.05 was considered significant in all tests.
Results
Patients
The demographic, biochemical, virological, and histopatho-
logical features of the patients with viral-associated HCC 
or non-HCC cirrhosis included in the study are shown in 
Additional file 2: Table S2. There were no significant differ-
ences in the distribution of gender and age; in all groups, the 
vast majority were male. The levels of serum aminotrans-
ferases and γ-glutamyltransferase showed the lowest values 
in patients with HBV-associated HCC, whereas the high-
est values were observed in HCV-associated HCC; HDV 
showed intermediate values. The levels of α-fetoprotein 
were instead higher in HBV-associated HCC compared to 
HCV or HDV-associated HCC (Additional file 2: Table S2). 
The grade of tumor differentiation was G2 in 13 patients, 
G3 in 11, and G4 in 1; HCC was surrounded by a cirrhotic 
liver in all but three patients with HCC. Thus, in more than 
85% of the cases, HCC arises on a cirrhotic liver, regardless 
of the viral etiology. The size of the tumor was comparable 
among the 3 groups of patients, with the majority of them 
presenting a size between 2 and 3  cm, and few patients 
showed histologically signs of vascular invasion (Additional 
file 2: Table S2). Among patients in the control group, the 
liver was either completely normal in 11 individuals (61%) 
or showed very scanty or mild fatty change in the remain-
ing 7 (39%); all patients but one had normal ALT levels. All 
were negative for serologic markers of active infection with 
hepatitis viruses (HBV, HCV, and HDV).
LncRNA expression profile in HBV‑, HCV‑, and HDV‑related 
HCC
To investigate if lncRNAs are differentially expressed in 
HCC of different viral etiology, we first employed the 
commercial Disease-Related Human LncRNA Profiler, 
which detects 83 lncRNAs implicated in a variety of 
human diseases, ranging from neurodegeneration to can-
cer, including 7 lncRNAs previously associated with HCC 
(ANRIL, H19, HOTAIR, HOTTIP, HULC, MALAT1 
and MEG3). A total of 50 liver specimens obtained from 
patients with HBV-, HCV- or HDV-associated HCC were 
analyzed (Fig. 1a).
Among the 83 lncRNAs tested, 15 were not detect-
able in any liver samples, including HOTAIR, which was 
previously reported to be associated with HCC [33]. 
The remaining 68 disease-related lncRNAs were used to 
investigate the relationship among the six groups of liver 
specimens: HBV-, HCV- and HDV-related HCC tissues 
and their surrounding non-tumorous tissues. Principal 
component analysis of the 68 lncRNA profiles showed 
a marked separation between tumor and non-tumor-
ous tissues (Fig.  1b), whereas no apparent differences 
were observed among tumors of different viral etiology 
(Fig. 1c).
Identification of lncRNAs dysregulated in HBV‑, HCV‑, 
and HDV‑related HCC
To identify lncRNAs that were differentially expressed in 
HBV-, HCV-, and HDV-related HCC, pairwise t-test com-
parisons between each hepatitis virus-associated HCC and 
paired adjacent non-tumorous tissues were performed on 
the 68 disease-related lncRNAs. We identified 17 lncRNAs 
that were dysregulated in at least one hepatitis virus-asso-
ciated HCC (Additional file  3: Table S3). To confirm our 
profiling data, we measured the expression levels of these 
17 lncRNAs by qRT-PCR using different sets of primers in 
liver specimens obtained from all 25 patients with HCC, as 
well as from 20 patients with HBV-, HCV-, or HDV-asso-
ciated cirrhosis without HCC and in control liver speci-
mens obtained from 10 liver donors and 8 liver resections 
for hemangioma (Fig. 2a; Additional file 4: Table S4). The 
majority (14 out of 17) of these lncRNAs were confirmed 
to be dysregulated in HCC compared to the surrounding 
non-tumorous tissues (Additional file 5: Table S5), corrob-
orating the reliability of our profiling data. To increase the 
stringency of our analysis, we focused on lncRNAs whose 
expression was at least twofold up- or down-regulated in 
tumor tissues compared to the surrounding non-tumorous 
tissues. Using this criterion, 10 lncRNAs were selected 
(Fig. 2b). The hierarchical clustering of these 10 lncRNAs 
(See figure on previous page.) 
Fig. 2 Differentially expressed lncRNAs in HBV-, HCV-, and HDV-related HCC, non-HCC cirrhosis and normal livers. a Study design illustrating the dif-
ferent groups of patients. b Hierarchical clustering based on the 10 lncRNAs differentially expressed in HBV-, HCV-, and/or HDV-related HCC. LncRNAs 
that are up-regulated are shown in shades of  red; those down-regulated are shown in shades of blue. The intensity of the color in each cell reflects 
the level of the corresponding lncRNA in the corresponding patient expressed as normalized log2 ratios. HCC-T, denotes hepatocellular carcinoma; 
HCC-NT, denotes surrounding non-tumorous tissue; CIR, denotes cirrhosis without HCC; NL, denotes normal liver from liver donors or liver resection 
for angioma. c Summary of dysregulatd lncRNAs in different hepatitis viruses-associated HCC tissues compared to their surrounding non-tumorous 
tissues. Names of up-regulated lncRNAs in HCC are shown in red and those down-regulated are shown in blue
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and the associated heat map show a separation between 
matched tumor and non-tumorous tissues, cirrhosis, and 
normal livers, indicating that most of the identified lncR-
NAs were selectively dysregulated in tumor samples. One 
of these lncRNAs, ANRIL, which displayed the high-
est expression in tumor tissues, was also up-regulated in 
non-tumorous tissues and in cirrhotic livers without HCC 
when compared to normal livers (Additional file 4: Table 
S4). Two of the selected 10 lncRNAs (ANRIL and HOT-
TIP) have previously been reported to be associated with 
HCC [34, 35]. Besides ANRIL and HOTTIP, none of the 
other 8 lncRNAs with  >twofold dysregulation was previ-
ously identified in HCC studies (Table  1). Two lncRNAs 
(BC017743 and BC043430) were found to be up-regulated 
and 6 (aHIF, LINC01152, PAR5, PCAT-29, TMEVPG1, 
and Y3) down-regulated in HCC tissues compared to 
paired adjacent non-tumorous tissues (Fig. 2c; Table 1).
Besides the 17 lncRNAs identified from our profil-
ing data, we also measured the expression levels of 18 
recently reported HCC-associated lncRNAs that were 
not included in our profiling analysis by qRT-PCR, using 
the same primers as previously reported [15–32] (Addi-
tional file 6: Table S6). In our study, only 7 of these lncR-
NAs (DBH-AS1, HEIH, hDREH, PCNA-AS1, hPVT1, 
UFC1 and ZEB1-AS1) were found to be significantly dys-
regulated in at least one hepatitis virus-associated HCC 
(Additional file 7: Table S7).
LncRNAs shared by HCC regardless of the viral etiology
Among the 8 newly identified HCC-related lncRNAs, 
BC017743 and BC043430 were highly expressed in all 
but one patient with HCC (24 out of 25; 96%) (Fig.  3a, 
b), with a fold change around 10 in each viral etiology 
(Table 1). Likewise, among the down-regulated lncRNAs, 
LINC01152 expression was reduced in all but one patient 
with HCC (24 out of 25, 96%) (Fig. 3c), and TMEVPG1 
in all but two (23 out of 25, 92%) (Fig. 3d), although the 
difference did not reach statistical significance in HBV-
related HCC (P = 0.099) (Table 1).
Among the lncRNAs previously reported in HCC, 
we found that 6 (ANRIL, HEIH, HOTTIP, PCNA-AS1, 
UFC1 and ZEB-AS1) were elevated in all three hepati-
tis viruses-related tumor tissues (Additional file 7: Table 
S7, Additional file 8: Figure S1a, b, f–i), although some of 
them did not reach statistical significance, possibly due to 
the small number of samples analyzed.
LncRNAs unique to HCC associated with a specific hepatitis 
virus
Next, we investigated whether some lncRNAs were spe-
cifically associated with a single hepatitis virus etiology. 
Interestingly, PCAT-29 was dysregulated predominantly 
in HBV-related HCC, aHIF and PAR5 in HCV-related 
HCC, and Y3 in HDV-related HCC (Fig. 2c). PCAT-29 was 
down-regulated in tumor vs. the surrounding non-tumor-
ous tissue of 8 out of 11 (73%) HBV-related HCC patients 
(P  =  0.004) (Fig.  4a; Table  1). Two lncRNAs, aHIF and 
PAR5, were significantly down-regulated in HCV-related 
HCC tissues (9 out of 10, 90% for both; P  =  0.001 and 
P = 0.005, respectively) (Fig. 4b, c; Table 1). Overexpression 
of Y3, which was previously reported in solid tumors, e.g. 
bladder, cervix, colon carcinoma [36], was found in only 3 
of 11 HBV-related HCC samples and 4 of 10 HCV-related 
HCC samples (Fig.  4d). Y3 was down-regulated in HDV-
related tumor tissues compared to the surrounding non-
tumorous tissues (P = 0.045) (Fig. 4d; Table 1).
Among the lncRNAs previously reported in HCC, we 
found that three lncRNAs, DBH-AS1, hDREH and hPVT1, 
behaved differently according to the hepatitis virus involved 
in HCC (Additional file  9: Figure S2a–c). DBH-AS1 was 
Table 1 Novel lncRNAs associated with HCC
Statistically significant P values were described in italic
P values were calculated by Student’s paired t-test. The positive sign (+) indicates upregulation of lncRNA expression in HCC; the negative sign (−) indicates 
downregulation of lncRNA expression in HCC
HCC denotes hepatocellular carcinoma, NT surrounding nontumorous tissue, HBV hepatitis B virus, HCV hepatitis C virus, HDV hepatitis D virus













aHIF 0.760 0.001 0.066 +1.159 −2.594 −2.707
BC017743 0.005 0.010 0.031 +9.279 +8.362 +7.774
BC043430 0.006 0.014 0.024 +11.562 +9.895 +8.551
LINC01152 0.038 0.003 0.041 −2.596 −4.453 −12.191
PAR5 0.580 0.005 0.121 −1.123 −2.074 −1.518
PCAT-29 0.004 0.343 0.515 −2.256 +2.454 −2.012
TMEVPG1 0.099 0.005 0.036 −4.318 −5.424 −5.108
Y3 0.198 0.653 0.045 −1.419 +1.077 −2.052
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found to be down-regulated in all HBV-related HCC sam-
ples (11 out of 11, 100%; P < 0.001) compared with adjacent 
non-tumor liver tissues (Additional file  7: Table S7, Addi-
tional file 9: Figure S2a). In contrast, this lncRNA was not 
significantly dysregulated in HCV- and HDV-related HCC 
tissues (Additional file 7: Table S7, Additional file 9: Figure 
S2a). Expression of hDREH was frequently reduced (8 out of 
11, 73%) in HBV-related HCC (Additional file 9: Figure S2b), 
as reported in a previous study [19], although this trend did 
not reach statistical significance (P  =  0.052) (Additional 
file 7: Table S7). On the contrary, hDREH was up-regulated 
in most cases of HCV-associated HCC (9 out of 10, 90%; 
P = 0.007) (Additional file 7: Table S7, Additional file 9: Fig-
ure S2b). Regarding hPVT1, we found that it was up-regu-
lated in our HBV-related HCC patients (10 out of 11, 91%; 
P = 0.004) (Additional file 7: Table S7, Additional file 9: Fig-
ure S2c). By contrast, the difference did not reach statistical 
significance in HCV-, and HDV-related HCC tissues (Addi-
tional file 7: Table S7, Additional file 9: Figure S2c).
Discussion
To the best of our knowledge, this is the first study in 
which the expression of lncRNAs was analyzed in paired 
tumorous and nontumorous liver specimens obtained 
from patients with HBV-, HCV-, and HDV-associated 
HCC. Although the number of patients that could be 
included in this comprehensive study was limited, our 
patients were well characterized in terms of clinical, viro-
logic and pathological features, and devoid of confound-
ing factors. It is estimated that 7000–23,000 lncRNAs 
exist in the human genome, with approximately 6700 
already identified [1]. However, only about 180 human 
lncRNAs recorded in the lncRNAdb (the reference data-
base for functional long noncoding RNAs) have been 
investigated and proved to be biologically functional [37]. 
In our study, we profiled 101 lncRNAs, which comprise 83 
lncRNAs included in Disease-Related Human LncRNA 
profiler and an additional 18 lncRNAs that have recently 
been associated with HCC [15–32]. Compared to previ-
ous studies of lncRNAs in HCC, which were mostly per-
formed in HBV-related HCC, we performed lncRNAs 
expression profiling in HCC associated with all three hep-
atitis viruses that cause chronic infection with the aim of 
investigating whether certain lncRNAs are selectively dys-
regulated according to the different viral etiology of HCC. 
Moreover, our study also included tissues from normal 
liver and cirrhosis without HCC, while most of the other 




























Fig. 3 Identification of novel lncRNAs dysregulated in HCC. Expression of lncRNAs in tumor and surrounding non-tumorous tissue in a series of 
patients with HCC-associated with HBV, HCV and HDV was analyzed by qRT-PCR. The expression levels of lncRNAs was normalized to the house 
keeping gene GAPDH. The Y axis indicates the relative expression of lncRNAs, calculated as described in the “Methods” section. a BC017743; b 
BC043430; c LINC01152; d TMEVPG1
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Access to a unique collection of paired liver samples 
from patients with HCC of different etiology allowed 
us to identify 8 lncRNAs that have not been previously 
associated with HCC. Six of these lncRNAs, namely, 
aHIF, BC017743, BC043430, PAR5, PCAT29 and Y3, 
have already been found to be dysregulated in other 
tumors [36, 38–41]. Except for Y3, the expression of 
five other cancer-related lncRNAs in HCC showed the 
same trend as previously reported in other tumors. aHIF 
was previously found to be down-regulated in breast 
cancer, where it can serve as a prognostic marker [38]. 
BC017743 and BC043430 are both located in the tumor 
suppressor region at 3p12.3. Dysregulation of BC017743 
and BC043430 has been found in lung, breast and kid-
ney cancers, but the function of these lncRNAs remains 
unclear [39]. Low expressions of PAR5 and PCAT29 were 
correlated with poor prognostic outcomes in human 
glioblastoma multiforme and prostate cancer, respec-
tively [40, 41]. Only PCAT29 has been shown to func-
tion as a tumor suppressor [41], while the functions 
of PAR5 have not been investigated. Overexpression 
of Y3 was found in bladder, cervix, colon, kidney, lung 
and prostate cancer where it seems to be required for 
cell proliferation [36]. However, we found that Y3 was 
significantly down-regulated in HDV-related HCC, indi-
cating a differential role of Y3 in the development of dif-
ferent cancers. Interestingly, our study provides the first 
evidence for an association between the remaining two 
lncRNAs, LINC01152 and TMEVPG1, and cancer, spe-
cifically HCC. LINC01152 was first identified in a patient 
with campomelic dysplasia, and its biological func-
tion remains to be fully elucidated [42]. We found that 
LINC01152 was also expressed in the liver and was fre-
quently down-regulated in HCC tissues, suggesting that 
it may play a role as a tumor suppressor. TMEVPG1 was 
found within the Tmevpg3 genetic locus which controls 
Theiler’s virus persistence [43]. We found its upregula-
tion seems to be related to liver cirrhosis, since no dif-
ference was observed between tumor and normal livers 
(Additional file 4: Table S4).
When we analyzed whether there was any relation-
ship between these 8 lncRNAs and a specific hepatitis 
virus associated with HCC, we found that 4 lncRNAs, 
BC017743, BC043430, LINC01152 and TMEVPG1, were 
highly up- or down-regulated in hepatitis viruses-related 
HCC. Interestingly, the other 4 lncRNAs, PCAT-29, 
aHIF, PAR5 and Y3, were significantly down-regulated 































Fig. 4 Identification of significantly dysregulated lncRNAs unique to HCC associated with a specific hepatitis virus. The expression of lncRNAs in 
the tumor and surrounding non-tumorous tissue in a series of patients with HCC-associated with HBV, HCV and HDV was analyzed by qRT-PCR. The 
expression levels of lncRNAs was normalized to the house keeping gene GAPDH. The Y axis indicates the relative expression of lncRNAs, calculated 
as described in the “Methods” section. a PCAT29; b aHIF; c PAR5; d Y3
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HCC: PCAT-29 in HBV-related HCC, aHIF and PAR5 
in HCV-related HCC, and Y3 in HDV-related HCC. 
This suggests that HCCs of different viral etiologies are 
regulated, at least in part, by different lncRNAs. Since 
there is very limited information about these lncR-
NAs, additional studies will be needed to elucidate the 
mechanistic connection between these lncRNAs and the 
molecular pathogenesis of HCC associated with differ-
ent hepatitis viruses. However, the identification of the 
lncRNA related to specific hepatitis virus-related HCC 
might be useful as accurate diagnostic markers for HCC 
of different viral etiology.
The Disease-Related Human LncRNA Profiler we 
employed in our study also includes several lncRNAs that 
were previously associated with HCC [34, 35, 44–46]. 
Our data are generally consistent with previous reports 
[34, 35, 44, 46]. For example, we found that ANRIL and 
HOTTIP expression levels were increased, while H19 and 
MEG3 expression levels were decreased, although these 
changes did not reach statistical significance in HCC tis-
sues due to dramatically elevated expression of these two 
lncRNAs in some tumor tissues (Additional file 8: Figure 
S1 c, e), as also reported in other studies [44, 46]. Our find-
ings show that these lncRNAs are commonly dysregulated 
in all hepatitis virus-associated HCC tissues, indicating 
that their functions in HCC are not associated with any 
specific hepatitis virus. In contrast to HOTTIP, H19 and 
MEG3, we found that ANRIL expression was up-regulated 
both in cirrhosis vs. normal liver and in HCC vs. cirrho-
sis, suggesting its involvement in the process of hepatocar-
cinogenesis from normal liver through the precancerous 
stage of cirrhosis. ANRIL is the antisense RNA of the 
tumor suppressor gene p15/CDKN2A, which can epige-
netically silence p15/CDKN2A in cis and in trans through 
heterochromatin formation or DNA methylation [47, 
48]. It is likely that ANRIL functions in HCC progression 
through the same mechanism, since the p15 promoter is 
frequently methylated in tumor tissues from HCC patients 
[49]. HULC, which was identified as the first hepatocyte-
specific lncRNA, was reported to be highly up-regulated in 
HCC [45, 50]. However, our data showed that changes in 
its expression were not statistically significant, being either 
up- or down-regulated in HCC tissues (Additional file 8: 
Figure S1d), indicating that the role of HULC in HCC 
might be more complex and requires further investigation.
Besides these previously reported HCC-related lncR-
NAs included in the profiler, more than 10 additional 
lncRNAs have been associated in HCC studies in the past 
5  years, which were mostly performed in HBV-related 
HCC [51]. In our analysis, three lncRNAs, DBH-AS1, 
hDREH and hPVT1, were differentially expressed accord-
ing to the viral etiology in HCC. Among these, both 
DBH-AS1 and hDREH are regulated by the HBV HBx 
protein [18, 19]. Thus, it is reasonable that they showed 
different expression patterns in HBV-related HCC com-
pared to HCV-related HCC. However, we also found 
something unexpected. In a previous report, the expres-
sion of DBH-AS1 was only analyzed in HCC tissues, and 
experimental evidence showed that this lncRNA pro-
motes cell proliferation and survival by activating MAPK 
signaling in HCC [18]. In our study, we found that DBH-
AS1 was down-regulated in all of our HBV-related HCC 
tissues compared to surrounding non-tumorous tissues, 
which appears to contradict its potential oncogenic role 
in HCC [18]. The lncRNA Dreh was previously found 
to be inhibited by HBx protein in mice and to act as a 
tumor suppressor in HBV-related HCC [19]. hDREH, the 
human homolog of Dreh, was significantly down-regu-
lated in HBV-related HCC tissues compared to the sur-
rounding non-tumorous tissues [19]. However, we found 
that hDREH was up-regulated in HCV-related HCC, 
which is contrary to what we and others have observed 
in HBV-related HCC, suggesting the existence of other 
factors that may affect hDREH expression besides HBx. 
Although HDV-related HCC patients were co-infected 
with HBV and HDV, HBV replication was reduced about 
100-fold compared to HBV-monoinfected cases [52], 
which might explain why DBH-AS1 and hDREH were not 
as significantly dysregulated in these patients as in HBV-
related HCC patients. The oncofetal lncRNA hPVT1 was 
found to promote proliferation and adoption of stem 
cell-like properties by HCC cells [27]. A previous report 
also showed that hPVT1 was up-regulated through the 
TGF-β pathway, which can be activated by HBV infection 
in HBV-associated HCC tissues [53]. Our data supports 
this conclusion by showing that hPVT1 was significantly 
up-regulated only in HBV-related HCC, not in HCV- and 
HDV-related HCC.
Several recently reported HCC-related lncRNAs were 
not significantly dysregulated in HCC tissues in our 
study. Besides the relatively limited sample size of our 
series, there are several other possible explanations for 
these findings. First, the difference between lncRNAs 
expression in tumor tissues compared to non-tumorous 
tissues in some instances, e.g. MVIH and LET [22, 25], 
was marginal (<onefold), which could be easily missed 
due to technical issues. Second, the method we used to 
detect some lncRNAs is different from those reported in 
other studies. For example, uc.338 expression was inves-
tigated in HCC tissues by in situ hybridization [28], while 
in our study we used qRT-PCR.
Conclusions
Our study provides new insights about the expression 
and potential role of lncRNAs in HCC. Since lncRNAs 
are emerging as key regulators of many cellular functions, 
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it will be important to investigate the role of these lncR-
NAs in HCC progression and their potential usefulness 
as diagnostic tools or therapeutic targets for HCC.
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